Bringing prognostic scores for chronic myeloid leukemia patients up to date

Expert Review of Hematology

Volumn 4, Issue 4, 2011, Pages 373-375

  Breccia, Massimo ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

chronic myeloid leukemia; imatinib; prognosis; second generation TKIs; tyrosine kinase inhibitor

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB;

CHROMOSOME 9; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; HUMAN; IC 50; OUTCOME ASSESSMENT; PHILADELPHIA 1 CHROMOSOME; PREMEDICATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT INDICATION;

FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 79961091096     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.35     Document Type: Review

References (25)

1. Deininger MW, O'Brien SG, Guilhot F et al. International randomized study of interferon vs STI571(IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 114 (2009) (Abstract 1126).
2. Milojkovic D, Apperley J.F. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukaemia. Clin. Cancer Res. 15(24), 7519-7527 (2009).
3. Gugliotta G, Castagnetti F, Palandri F et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML WP. Blood 117(21), 5591-5599 (2011).
4. Castagnetti F, Testoni N, Luatti S et al. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. J. Clin. Oncol. 28(16), 2748-2754 (2010).
5. Marzocchi G, Castagnetti F, Luatti S et al. Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA WP on CML analysis. Blood DOI: 10.1182/blood-2011-01-328294 (2011) (Epub ahead of print).
6. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in good-risk chronic granulocytic leukemia. Blood 63(4), 789-799 (1984). (Pubitemid 14141296)
7. Hasford J, Pfirrmann M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon a. Writing committee for the Collaborative CML Prognostic Factors Project Group. J. Natl Cancer Inst. 90(11), 850-858 (1998). (Pubitemid 28280552)
8. Hughes TP, Kaeda J, Branford S et al. Frequency of major molecular responses to imatinib or interferon a plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349(15), 1423-1432 (2003). (Pubitemid 37211057)
9. Kantarjian HM, Talpaz M, O'Brien S et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic phase myeloid leukemia after failure of interferon-a: follow-up results. Clin. Cancer Res. 8(7), 2177-2187 (2002). (Pubitemid 34753588)
10. White DL, Hughes TP. Predicting the response of CML patients to tyrosine kinase inhibitor therapy. Curr. Hematol. Malig. Rep. 4, 59-65 (2009).
11. White DL, Saunders VA, Dang P et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity. Higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110, 4064-4072 (2007). (Pubitemid 350248463)
12. Mahon FX, Belloc F, Lagarde V et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101, 2368-2373 (2003). (Pubitemid 36304670)
13. Dulucq S, Bouchet S, Turcq B et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 11, 2024-2027 (2008).
14. Picard S, Titier K, Etienne G et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109, 3496-3499 (2007). (Pubitemid 46572540)
15. Larson RA, Druker BJ, Guilhot F et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a sub-analysis of the IRIS study. Blood 111, 4022-4028 (2008).
16. Quintas-Cardama A, Kantarjian H, Jones D et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113(25), 6315-6321 (2009).
17. Hughes TP, Branford S. Molecular monitoring of chronic myeloid leukemia. Semin. Hematol. 40(2), 62-68 (2003).
18. Baccarani M, Cortes J, Pane F et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 27(35), 6041-6051 (2009).
19. Milojkovic D, Nicholson E, Apperley JF et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 95(2), 224-231 (2010).
20. Breccia M, Stagno F, Gozzini A et al. Hammersmith score application is able to identify chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors. Am. J. Hematol. 86(6), 523-525 (2011).
21. Jabbour E, Kantarjian H, O'Brien S et al. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood 117(6), 1822-1827 (2011).
22. Breccia M, Latagliata R, Stagno F et al. Assessment of MDACC prognostic score for imatinib resistant CML patients. Blood (2010) (E-letter).
23. Saglio G, Kim DW, Issaragrisil S et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362(24), 2251-2259 (2010).
24. Kantarjian H, Shah NP, Hochhaus A et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 362(24), 2260-2270 (2010).
25. Hasford J, Baccarani M, Hoffmann V et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118(3), 686-692 (2011).